Structure Therapeutics Inc.
GPCR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001888886
No open-market purchases or sales by Structure Therapeutics Inc. insiders were filed in the last 90 days; 191 institutions reported holding it in 13F filings for Q2 2026, worth $3.62B in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Structure Therapeutics Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 119
- −2 vs. Q4 2023
- Shares held
- 43.6M
- +965.5K (+2.3%) vs. Q4 2023
- Total value
- $1.86B
- +$123.2M (+7.1%) vs. Q4 2023
- New holders
- 24
- 46 more added
- Sold out
- 26
- 35 more reduced
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GPCR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 191 | $3.62B |
| Q1 2026 | 198 | $3.23B |
| Q4 2025 | 199 | $4.58B |
| Q3 2025 | 158 | $1.59B |
| Q2 2025 | 173 | $1.14B |
| Q1 2025 | 151 | $990.0M |
| Q4 2024 | 165 | $1.65B |
| Q3 2024 | 161 | $2.69B |
| Q2 2024 | 167 | $2.33B |
| Q1 2024 | 119 | $1.86B |
| Q4 2023 | 122 | $1.74B |
| Q3 2023 | 84 | $1.64B |
| Q2 2023 | 48 | $699.4M |
| Q1 2023 | 38 | $346.2M |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Structure Therapeutics Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 812,988 | $34.8M | 0.96% | 00.0% | Unchanged |
| Avidity Partners Management LP | 864,000 | $37.0M | 1.32% | −216,000−20.0% | Reduced |
| SC China Holding Ltd | 1,064,982 | $38.4M | 3.56% | −2440.0% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 1,033,680 | $44.3M | 0.77% | +210,867+25.6% | Added |
| BlackRock Inc. | 1,086,413 | $46.6M | 0.00% | +25,355+2.4% | Added |
| Casdin Capital, LLC | 1,116,867 | $47.9M | 3.56% | +25,000+2.3% | Added |
| T. Rowe Price Investment Management, Inc. | 1,216,303 | $52.1M | 0.03% | −95,892−7.3% | Reduced |
| Citadel Advisors LLC | 1,275,862 | $54.7M | 0.05% | +122,877+10.7% | Added |
| Capital International Investors | 1,281,564 | $54.9M | 0.01% | +431,540+50.8% | Added |
| Alyeska Investment Group, L.P. | 1,300,986 | $55.8M | 0.35% | +1,122,309+628.1% | Added |
| Ra Capital Management, L.P. | 1,510,362 | $64.7M | 0.82% | +1,023,530+210.2% | Added |
| Capital Research Global Investors | 1,527,483 | $65.5M | 0.01% | +553,948+56.9% | Added |
| Price T Rowe Associates Inc | 1,560,950 | $66.9M | 0.01% | −118,486−7.1% | Reduced |
| TCG Crossover Management, LLC | 1,598,421 | $68.5M | 5.42% | −511,163−24.2% | Reduced |
| Janus Henderson Group PLC | 2,076,700 | $89.0M | 0.05% | +532,284+34.5% | Added |
| Federated Hermes, Inc. | 2,257,206 | $96.7M | 0.22% | −10,000−0.4% | Reduced |
| Driehaus Capital Management LLC | 2,490,303 | $106.7M | 1.06% | −108,776−4.2% | Reduced |
| FMR LLC | 2,948,764 | $126.4M | 0.01% | −1,085,820−26.9% | Reduced |
| Wellington Management Group LLP | 5,827,656 | $249.8M | 0.04% | +1,455,330+33.3% | Added |
| Avoro Capital Advisors LLC | 0 | $0 | 0.00% | −2,333,333−100.0% | Sold out |
| MPM Oncology Impact Management LP | 0 | $0 | 0.00% | −230,696−100.0% | Sold out |
| Pictet Asset Management Holding SA | 0 | $0 | 0.00% | −138,797−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −125,447−100.0% | Sold out |
| Bamco Inc | 0 | $0 | 0.00% | −118,333−100.0% | Sold out |
| GMT Capital Corp | 0 | $0 | 0.00% | −81,700−100.0% | Sold out |
| Exome Asset Management LLC | 0 | $0 | 0.00% | −68,100−100.0% | Sold out |
| Weiss Multi-Strategy Advisers LLC | 0 | $0 | 0.00% | −48,914−100.0% | Sold out |
| Parkman Healthcare Partners LLC | 0 | $0 | 0.00% | −38,678−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −29,414−100.0% | Sold out |
| E Fund Management Co., Ltd. | 0 | $0 | 0.00% | −28,589−100.0% | Sold out |
| Kennedy Capital Management, Inc. | 0 | $0 | 0.00% | −25,876−100.0% | Sold out |
| Twinbeech Capital LP | 0 | $0 | 0.00% | −24,290−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −17,914−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −16,300−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −14,524−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −13,879−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −13,700−100.0% | Sold out |
| First Trust Advisors LP | 0 | $0 | 0.00% | −12,967−100.0% | Sold out |
| Voya Investment Management LLC | 0 | $0 | 0.00% | −9,730−100.0% | Sold out |
| Temasek Holdings (Private) Ltd | 0 | $0 | 0.00% | −9,617−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −9,200−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −5,705−100.0% | Sold out |
| Picton Mahoney Asset Management | 0 | $0 | 0.00% | −2,410−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −679−100.0% | Sold out |
| Able Wealth Management LLC | 0 | $0 | 0.00% | −14−100.0% | Sold out |
| Fairfield Financial Advisors, LTD | – | – | – | – | Not filed |